Dr. Fred Saad describes the results of the PROpel Phase III trial of abiraterone and olaparib versus abiraterone and placebo in patients with mCRPC.
The Uromigos Episode 158: ASCO GU 2022 PROpel Phase III Olaparib and Abiraterone in mCRPC
By The Uromigos - Last Updated: November 11, 2022
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.